Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia.
Published on May 20, 2015in Journal of Clinical Oncology28.349
· DOI :10.1200/JCO.2015.33.15_SUPPL.E18024
e18024 Background: Tyrosine kinase inhibitors are the mainstay of treatment of chronic myeloid leukemia (CML). Recently, four different generic Imatinib formulations were approved for the frontline...